Combination Chemotherapy Consisting of Pegylated Liposomal Doxorubicin and Carboplatin in Malignant Gynecologic Tumours

Inclusion Criteria: * Histologically confirmed diagnosis of a gynecologic tumour \[(non-epithelial ovarian tumour without germcell-tumours, tumours of the uterus (eg. Muellerian mixed tumours, Endometrial carcinomas, Uterus sarcoma, Cancer of the cervix)\] * Target or non-target lesion. Patients with epithelial ovarian carcinoma are qualified also if they have a CA 125 increase only. * Patients with ovarian carcinoma must have completed a platin-containing chemotherapy more than 6 months at least. Patients with other malignancies could have prior chemotherapy, but must'nt * Prior Radiotherapy less than 25% of haemapoietic system is allowed, but should have completed at least 6 weeks prior or registration * Prior antitumoral hormone therapy, or specific immunotherapy is allowed, treatment have to be completed at least 3 weeks prior of registration * All women with childbearing potential have to be a negative pregnancy test within 7 days of registration * Perfomance Status 0-2 ECOG or more than 60% according to Karnofsky Index * Estimated expectancy of life of more than 12 weeks * adequate hematologic, renal and hepatic function according to following definitions: absolute Neutrophils \>= 1,5 n/L Platelets \>= 100 n/L Bilirubine \<= 1,25 x ULN estimated glomerular filtration rate (Jelliffe) \>= 60 ml/min * Patients who have given their signed and written informed consent to participate in the trial * Patients must be geographically accessible for treatment and follow Exclusion Criteria: * More than 2 prior chemotherapies (or Radio-Chemotherapies) * active infection or concurrent severe medical problems unrelated to malignancy which would significantly limit full compliance with the study or expose the patient to extreme risk or decreased life expectancy * application of other cytotoxic or antitumoral agents during study period * Patients with a history of seizure disorder or central nervous system disorders * History of congestive heart failure (NYHA Classification \> 2, even if medically controlled. * History of clinical and electrocardiographically documented myocardial infarction within the last 6 months. * History of atrial or ventricular arrhythmias (\> LOWN II) * Women who are pregnant or breast feeding * Fertile women not using adequate contraceptive measures * Patients who have used any investigational drugs within 30 days of study entry